DelveInsight’s “Epilepsy Market Insights, Epidemiology and Market Forecast – 2036” report delivers an in-depth understanding of Epilepsy, historical and forecasted epidemiology as well as the Epilepsy therapeutics market trends in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.
Unlock detailed insights into the Epilepsy Market by downloading the comprehensive report from DelveInsight @ https://www.delveinsight.com/sample-request/epilepsy-market?utm_source=pngw&utm_medium=pr&utm_campaign=kkpr
Key Takeaways from the Epilepsy Market Report
- In March 2026, Xenon Pharmaceuticals Inc. announced positive topline results from the Phase III (X-TOLE2) study of azetukalner in focal onset seizures (FOS). Xenon anticipates submitting a New Drug Application for azetukalner in FOS to the U.S. FDA in Q3 2026. If approved, azetukalner would be the only KV7 potassium channel opener available for the treatment of epilepsy.
- In January 2026, Biohaven announced preliminary data from an ongoing open-label extension (OLE) study of opakalim, a selective Kv7 channel activator, in focal epilepsy, with pivotal results in the indication expected in 2026.
- In April 2025, Neurelis, Inc. announced FDA approval of VALTOCO (diazepam nasal spray) for the short-term treatment of seizure clusters (acute repetitive seizures) in patients aged 2 years and older.
- According to DelveInsight’s analysis, in 2025, the total number of individuals living with Epilepsy globally is approximately 50-70 million, making it one of the most common chronic neurological disorders globally.
- The US had the highest cases of epilepsy, of which nearly 67% of the cases were focal epileptic seizures, 31% were generalized epileptic seizures, while 2% of the cases were other determined or undetermined epileptic seizures.
- Epidemiological studies indicate that the prevalence of epilepsy in the general population is approximately 0.5-1.0% (5-10 per 1,000 individuals), with a higher burden observed in low- and middle-income countries due to increased risk factors and limited access to care.
- Focal epilepsy accounts for approximately 67% of all cases, while generalized epilepsy represents 20-30%, with the remaining cases classified as unknown or combined onset types.
- Secondary epidemiological analyses highlight that incidence follows a bimodal age distribution, with peaks in early childhood and adults over 60 years, largely driven by genetic causes in pediatric patients and cerebrovascular disease in older adults.
- Despite therapeutic advancements, Epilepsy remains a high-burden neurological disorder with significant morbidity, psychosocial impact, and treatment resistance in approximately 30% of patients, representing a major unmet need.
- The leading Epilepsy Companies such as Neurelis, Inc. , BIOCODEX , Aquestive Therapeutics , ONO PHARMACEUTICAL CO., LTD. , Biohaven , Xenon Pharmaceuticals Inc. , Meda Pharmaceuticals, Autifony Therapeutics , Greenwich Biosciences , GSK , Roche, Lundbeck , Eisai Pharmaceuticals India , Johnson & Johnson , and others.
- Promising Epilepsy Therapies such as Azetukalner (XEN1101), Opakalim (BHV-7000), Relutrigine (PRAX-562), Benzodiazepine (STACCATO alprazolam), Ganaxolone (ZTALMY), Cannabidiol (EPIDIOLEX), Brivaracetam (BRIVIACT), and others.
Gain a competitive edge in the Epilepsy Market by exploring our in-depth analysis @ https://www.delveinsight.com/sample-request/epilepsy-market?utm_source=pngw&utm_medium=pr&utm_campaign=kkpr
Epilepsy Epidemiology Segmentation in the 7MM
- Total Prevalent Population of Epilepsy
- Total Diagnosed Prevalent Population of Epilepsy
- Gender-specific Diagnosed Prevalence of Epilepsy
- Diagnosed Prevalence of Epilepsy Based on Seizure Types in Adults
- Diagnosed Prevalence of Epilepsy Based on Seizure Types in Children
- Age-specific Diagnosed Prevalence of Epilepsy
Download the report to understand which factors are driving Epilepsy Epidemiology Trends @ https://www.delveinsight.com/sample-request/epilepsy-market?utm_source=pngw&utm_medium=pr&utm_campaign=kkpr
Epilepsy Treatment Landscape
Epilepsy is a chronic neurological disorder characterized by recurrent, unprovoked seizures due to abnormal, excessive, and synchronous neuronal electrical activity in the brain. The management of epilepsy involves a comprehensive approach to reduce seizures, enhance quality of life, and manage associated issues, although no treatment provides a cure. Treatment of Epilepsy is primarily based on long-term use of anti-seizure medications (ASMs) aimed at controlling recurrent seizures and improving quality of life. First-line therapies include sodium channel blockers (such as carbamazepine, lamotrigine), SV2A modulators (such as levetiracetam, brivaracetam), and GABAergic agents, selected based on seizure type and patient profile. In drug-resistant cases, adjunctive therapies such as cannabidiol (Epidiolex), fenfluramine (Fintepla), and other syndrome-specific agents are used to reduce seizure frequency. For refractory epilepsy, non-pharmacological options include epilepsy surgery, vagus nerve stimulation (VNS), responsive neurostimulation (RNS), and ketogenic diet therapy. Numerous anti-epileptic drugs (AEDs) have been approved, many available in generic form, such as lamotrigine, sodium valproate, carbamazepine, levetiracetam, and topiramate. Despite the availability of multiple ASMs, nearly 30-40% of patients develop drug-resistant epilepsy (DRE), highlighting a significant unmet need and driving innovation toward therapies with novel mechanisms of action and improved tolerability.
Epilepsy Emerging Therapy Assessment
- Azetukalner (XEN1101): Xenon Pharmaceuticals Azetukalner, developed by Xenon Pharmaceuticals, is a novel, orally administered, potent, selective KCNQ2/3 (Kv7.2/7.3) potassium channel opener being developed to treat epilepsy in focal onset seizures and primary generalized tonic-clonic seizures (PGTCS). It acts as a neuronal Kv7 voltage-gated potassium channel opener and has been developed to stabilize nerve cells, control action potential burst firing, and reduce brain hyper-excitability as a seizure treatment. In April 2026, Xenon Pharmaceuticals presented Azetukalner Phase III X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at the 2026 American Academy of Neurology Annual Meeting.
- Opakalim (BHV-7000): Biohaven Pharmaceuticals BHV-7000 is a potent, selective KCNQ2 potassium channel activator being developed for epilepsy and other neurological disorders. By stabilizing neuronal hyper-excitability, it targets the underlying mechanisms of seizures. Opakalim consistently demonstrates exceptional tolerability across all stages of development. In focal epilepsy Phase II/III OLE, data showed a 50% responder rate comparable to other ASMs, along with low rates of adverse events. Pivotal results for opakalim in the treatment of focal epilepsy are expected in the second half of 2026.
- Ganaxolone (ZTALMY): Marinus Pharmaceuticals Ganaxolone, developed by Marinus Pharmaceuticals, is a small molecule GABA A receptor modulator that was approved in the US in 2022 and in the EU in 2023. It represents a shift toward mechanism-specific and syndrome-targeted approaches in epilepsy treatment.
- Cannabidiol (EPIDIOLEX): Jazz Pharmaceuticals Cannabidiol, developed by GW Pharmaceuticals, is a cannabidiol medication that was approved in the US by the FDA in 2018 and later by EMA in 2019 for patients aged 2 years and older with Dravet syndrome or Lennox-Gastaut syndrome. CBD possesses an affinity for multiple targets, resulting in functional modulation of neuronal excitability, relevant to the pathophysiology of epilepsy.
Discover key developments and opportunities in the Epilepsy Market @ https://www.delveinsight.com/sample-request/epilepsy-market?utm_source=pngw&utm_medium=pr&utm_campaign=kkpr
Epilepsy Market Outlook
The epilepsy market is undergoing a progressive shift from broad-spectrum anti-seizure medications (ASMs) toward more targeted and mechanism-driven therapies, although sodium channel blockers and GABAergic agents such as levetiracetam, valproate, and lamotrigine continue to dominate first-line treatment. Despite the availability of multiple ASMs, nearly 30-40% of patients develop drug-resistant epilepsy (DRE), highlighting a significant unmet need and driving innovation toward therapies with novel mechanisms of action and improved tolerability. The increasing use of rescue therapies such as diazepam nasal spray and midazolam nasal spray reflects a growing emphasis on outpatient seizure management and rapid intervention.
With the advancement of next-generation targeted therapies, the epilepsy landscape is evolving similarly to other neurological disorders, where innovation is driven by precision mechanisms and disease subtyping. Emerging agents such as cenobamate, ganaxolone, azetukalner, and opakalim are designed to address neuronal hyperexcitability through differentiated pathways, including selective potassium channel modulation and neurosteroid mechanisms. In addition, cannabidiol-based therapies have expanded treatment options for rare and severe epileptic syndromes, reinforcing the shift toward mechanism-specific and syndrome-targeted approaches.
The United States continues to represent the largest epilepsy market, driven by a high diagnosed patient population, strong reimbursement frameworks, and rapid uptake of novel therapies. Increasing awareness, improved diagnosis rates, and expansion of treatment options for rare epileptic encephalopathies are further supporting market growth. Overall, the introduction of first-in-class and best-in-class therapies, along with innovation in rescue treatments and precision medicine, is expected to drive steady growth in the 7MM epilepsy market from 2026-2036, with significant commercial opportunities across both established and emerging therapies.
Scope of the Epilepsy Market Report
- Coverage: 7MM
- Study Period: 2022-2036
- Epilepsy Companies: Neurelis, Inc. , BIOCODEX , Aquestive Therapeutics , ONO PHARMACEUTICAL CO., LTD. , Biohaven , Xenon Pharmaceuticals Inc. , Meda Pharmaceuticals, Autifony Therapeutics , Greenwich Biosciences , GSK , Roche, Lundbeck , Eisai Pharmaceuticals India , Johnson & Johnson , and others.
- Epilepsy Pipeline Therapies: Azetukalner (XEN1101), Opakalim (BHV-7000), Relutrigine (PRAX-562), Benzodiazepine (STACCATO alprazolam), Ganaxolone (ZTALMY), Cannabidiol (EPIDIOLEX), Brivaracetam (BRIVIACT), and others.
- Epilepsy Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Epilepsy Unmet Needs, KOL’s views, Analyst’s views, Epilepsy Market Access and Reimbursement
Download DelveInsight’s Epilepsy Market report today and stay ahead in this rapidly evolving field @ https://www.delveinsight.com/sample-request/epilepsy-market?utm_source=pngw&utm_medium=pr&utm_campaign=kkpr
Table of Contents
- Key Insights
- Report Introduction
- Executive Summary
- Key Events
- Epidemiology and Market Methodology of Epilepsy
- Epilepsy Market Overview at a Glance
- Disease Background and Overview of Epilepsy
- Epidemiology and Patient Population of Epilepsy
- Patient Journey of Epilepsy
- Marketed Therapies
- Emerging Therapies
- Epilepsy: Seven Major Market Analysis
- Unmet Needs of Epilepsy
- SWOT Analysis of Epilepsy
- KOL Views of Epilepsy
- Market Access and Reimbursement of Epilepsy
- Appendix
- DelveInsight Capabilities
- Disclaimer
- About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Contact Us
Kanishk
kkumar@delveinsight.com
